Karyopharm Therapeutics Inc. financial data

Symbol
KPTI on Nasdaq
Location
85 Wells Avenue, Second Floor, Newton, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 355 % -25.5%
Quick Ratio 4.87 % -24.4%
Debt-to-equity -273 % +49.8%
Return On Equity 66.9 % -67.7%
Return On Assets -38.7 % +17.1%
Operating Margin -89.9 % -4.85%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 125M shares +9.03%
Common Stock, Shares, Outstanding 125M shares +9%
Entity Public Float 201M USD -42.8%
Common Stock, Value, Issued 13K USD +8.33%
Weighted Average Number of Shares Outstanding, Basic 121M shares +5.97%
Weighted Average Number of Shares Outstanding, Diluted 154M shares +35.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 146M USD -0.23%
Research and Development Expense 149M USD +17.9%
Operating Income (Loss) -131M USD -4.61%
Nonoperating Income (Expense) 41.3M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -89.6M USD +36.6%
Income Tax Expense (Benefit) 280K USD -6.36%
Net Income (Loss) Attributable to Parent -89.9M USD +36.5%
Earnings Per Share, Basic -0.83 USD/shares +43.2%
Earnings Per Share, Diluted -1.18 USD/shares +19.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 84.8M USD +4.8%
Inventory, Net 3.48M USD -5.34%
Other Assets, Current 31.5M USD
Assets, Current 209M USD -28.4%
Property, Plant and Equipment, Net 628K USD -18%
Operating Lease, Right-of-Use Asset 3.17M USD -40.1%
Assets 214M USD -28.2%
Accounts Payable, Current 2.8M USD +22.3%
Employee-related Liabilities, Current 16.5M USD -15.9%
Accrued Liabilities, Current 49.8M USD -3.86%
Liabilities, Current 57.6M USD -2.22%
Operating Lease, Liability, Noncurrent 955K USD -78.8%
Other Liabilities, Noncurrent 4.28M USD +75.8%
Liabilities 346M USD -6.22%
Accumulated Other Comprehensive Income (Loss), Net of Tax -605K USD +22.7%
Retained Earnings (Accumulated Deficit) -1.5B USD -6.37%
Stockholders' Equity Attributable to Parent -132M USD -85.5%
Liabilities and Equity 214M USD -28.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.7M USD -131%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 21.9M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 125M shares +9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.8M USD +57.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 85.1M USD +3.99%
Deferred Tax Assets, Valuation Allowance 412M USD +8.62%
Deferred Tax Assets, Gross 1.03M USD -32%
Operating Lease, Liability 6.1M USD -32%
Depreciation 85K USD -70.7%
Payments to Acquire Property, Plant, and Equipment 195K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -89.7M USD +36.7%
Lessee, Operating Lease, Liability, to be Paid 6.74M USD -35.6%
Property, Plant and Equipment, Gross 7.17M USD -7.88%
Operating Lease, Liability, Current 3.55M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.92M USD -23.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.82M USD +2.66%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 638K USD -57%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.92M USD -23.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 20.6M USD -15.5%
Interest Expense 27.1M USD +15.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%